Anti-Human Fractalkine (Clone 81513)
Anti-Human Fractalkine (Clone 81513) (C1406-GRP)
Products
Description
Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | C1406 |
| Formulation | This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present. |
| Alternate Names | Monoclonal Antibody Fractalkine CX3CL1 NTN ABCD-3 C3Xkine CXC3 CXC3C NTT SCYD1 Neurotactin FKN 81513 FKN Human Anti-Human Fractalkine |
| Isotype | IgG1 |
| Clone | 81513 |
| Target | Fractalkine |
| Antibody Type | Monoclonal |
| Applications | IHC FFPE, WB |
| Storage | -20°C to -70°C |
| Protein | Fractalkine |